Department of Nephrology and Transplantology, Medical University, Bialystok, Poland.
Transpl Int. 2012 Oct;25(10):1013-23. doi: 10.1111/j.1432-2277.2012.01513.x. Epub 2012 Jun 21.
Anemia is a highly prevalent disorder in recipients of renal allografts. Despite its frequent occurrence, there is still uncertainty with regard to treatment targets and treatment options. This includes questions on appropriate iron management, the choice and dosage of erythropoietin stimulating agents, criteria for the timing of treatment initiation and the targeted hemoglobin values. The review summarizes available data on recent therapeutic strategies for post transplant anemia, as well as for post transplant erythrocytosis, another hematological disorder, that has decreased in recent years.
贫血是肾移植受者中一种高发疾病。尽管贫血很常见，但在治疗目标和治疗方案方面仍存在不确定性。这包括关于适当的铁管理、促红细胞生成素刺激剂的选择和剂量、治疗开始时机的标准以及目标血红蛋白值的问题。本文综述了最近关于移植后贫血以及近年来发病率降低的另一种血液学疾病——移植后红细胞增多症的治疗策略的可用数据。
